What is the difference between myelodysplastic syndrome and multiple myeloma?

Myelodysplastic syndrome (MDS) is a hematopoietic dysfunction caused by abnormal proliferation and differentiation of hematopoietic stem cells. The main manifestations are peripheral blood pancytopenia, bone marrow cell proliferation, and morphological abnormalities of mature and naïve cells, that is, pathological hematopoiesis.

Multiple myeloma is a malignant tumor with abnormal proliferation of plasma cells. A progressive neoplastic disease. It is characterized by myeloplasmacytoma and an intact monoclonal immunoglobulin (IgG, IGGA, IGD, or IgE) or Bence Jones protein (free monoclonal or light chain) hyperplasia.

Multiple myeloma is often associated with multiple lytic lesions, hypercalcemia, anemia, and renal damage.

Myelodysplastic syndrome is not a malignant tumor, but some of them will be transformed into leukemia, and most of them can still be saved through the combination of traditional Chinese and Western medicine**. Multiple myeloma is a malignant tumor with a very high mortality rate and greater difficulty.

Myelodysplastic syndromes (MDS) are a heterogeneous group of acquired clonal disorders, the basic lesions of which are clonal hematopoietic trunk and dysplasia, resulting in ineffective hematopoiesis and an increased risk of malignant transformation. Manifested by an increased or normal number of hematopoietic cells of all lines in the bone marrow, but morphological changes with obvious dysplasia; There is a marked decrease in blood cells of all lineages in the peripheral blood. It also evolved into acute myeloid leukemia (acute

myeloid

Leukemia, AML) is at high risk.

Multiple myeloma (MM) is the most common type of malignant plasma cell disease, also known as myeloma, plasma cell myeloma or Kahler disease. It was not until 1889, when Kahler reported cases in detail, that multiple myeloma became widely known and recognized. Multiple myeloma is characterized by malignant proliferation of monoclonal plasma cells and secretion of large amounts of monoclonal immunoglobulins.

The incidence is estimated at 2,3100,000, with a male-to-female ratio of 1, most of whom are 40 years old, and twice as many black patients as whites.

Myelodysplastic syndrome is an abnormal myeloproliferative syndrome, in which abnormal hematopoietic cells appear, but the abnormality of this cell is not abnormal enough to diagnose leukemia, so myelodysplastic syndrome used to have a name called pre-leukemia. Of course, over time, many myelodysplastic syndromes may eventually progress to leukemia. It is an exclusionary diagnosis, when the previous blood system has abnormalities, has a tendency to tumor, feels like leukemia, but does not reach the case of leukemia, excludes aplastic anemia, excludes PNH and other clearly diagnosed blood diseases, and classifies it into myelodysplastic syndrome, it is actually a group of diseases with a variety of blood system abnormalities that are not particularly clearly classified.

Myelodysplastic syndrome (MDS) is a group of heterogeneous acquired malignant diseases originating from hematopoietic stem cells, and its basic lesions are clonal hematopoietic stem, abnormal development of progenitor cells or refractory cytopenia caused by bone marrow failure, obvious pathological hematopoiesis and ineffective hematopoiesis in trilineage cells, and high-risk transformation of acute myeloid leukemia.

It is not a malignant tumor, but high-risk MDS can easily transform into acute myeloid leukemia.

Myelodysplastic syndrome is a type of cancer, mainly a malignant tumor in the blood system. During this period, patients may have some poor hematopoietic quality, or even ineffective hematopoiesis, and the lifespan of blood cells has been drastically shortened. If you need to consult the condition or medication guidance, you can click [Official Service-Official**] below to get help.

Hello friends don't worry, in this case myeloproliferative syndrome part of the RAS is effective for vitamin B6 **, 200 500mg intravenous drip a day, which can increase reticulocytes and reduce the amount of blood transfusion.

Myelodysplastic syndrome bone marrow smear can show significant pathological hematopoiesis, while myeloproliferative disorders do not, which is the main differentiating point.

Myelodysplastic syndromes are a group of acquired, severely disordered hematopoietic and hematopoietic stem cell clonal disorders.

Biopsy of the osteop.

In most cases, the bone marrow hematopoietic tissue is hyperplasia, and the main findings are immature granulocytosis and abnormal localization of immature precursor cells. Normally, myelocytes and promyelocytes are located on the surface of the endosteal, and in MDS, these two cells are clustered and located in the bone marrow**. Changes in megakaryotic morphology, localization abnormalities, and reticular fibrous hyperplasia may also be seen.

Multiple myeloma.

Bone marrow aspirate is decisive for the diagnosis. In early patients, tumor cells can be focal, so multiple punctures are required to help diagnose the disease, and the tumor cells are often stacked at the tail of the smear. Bone condyls are generally hyperplasia, and the proportion of each system often varies with the number of tumor cells.

When the proportion of tumor cells is high, granulocytes and erythroid cells are significantly reduced. Normal plasma cells in the bone marrow are 1%, and in multiple myeloma, abnormal plasma cells are increased, generally 5% to 10%, and most can be as high as 70% to 95%. The size, morphology, and maturity of the tumor cells are markedly abnormal.